Status:
WITHDRAWN
Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy
Lead Sponsor:
University Hospital, Akershus
Collaborating Sponsors:
Oslo University Hospital
AstraZeneca
Conditions:
Depression
Eligibility:
All Genders
40-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate whether rosuvastatin decreases measures of inflammation in depressive patients.
Detailed Description
Depression is associated with increased risk of cardiovascular disease, in which one possible mechanism is systemic inflammation. Further, patients at high risk of cardiovascular disease, rosuvastatin...
Eligibility Criteria
Inclusion
- Persisting self-reported depressive symptoms \> 5 weeks
- Indications of aortic atherosclerosis on PET/CT
Exclusion
- Clinical indication of statin use.
- Contraindication of statins, or of PET/CT and MRI.
- Established cardiovascular disease.
- Bipolar disorder og comorbid psychosis.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00951132
Start Date
September 1 2009
End Date
December 1 2013
Last Update
February 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Akershus University Hospital
Lorenskog, Akershus, Norway, 1478